| COMPARATIVE-EFFECTIVENESS RESEARCH/HTA S Tanaka, A Igarashi, R De Moor, N Li, M Hirozane, LW Hong, DBC Wu, ... | | 2024 |
| A targeted review of worldwide indirect treatment comparison (ITC) guidelines and best practices S Tanaka, A Igarashi, R De Moor, N Li, M Hirozane, LW Hong, DBC Wu, ... Value in Health, 2024 | | 2024 |
| HTA79 CADTH Reimbursement Recommendations for Mental Illness Health Products: 10-Year Trends in Relation to Non-Mental Illness Health Products and Recommendations From Other … S Singh, M Spence, C Cameron, D Gallson Value in Health 26 (12), S333, 2023 | | 2023 |
| Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant EH Law, C Cameron Journal of Comparative Effectiveness Research 12 (6), e230009, 2023 | | 2023 |
| The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: An analysis of the prospective MDS-CAN registry R Buckstein, L Chodirker, KWL Yee, M Geddes, HA Leitch, G Christou, ... Leukemia & Lymphoma 64 (3), 651-661, 2023 | 5 | 2023 |
| Building infrastructure for outcomes-based agreements in Canada: can administrative health data be used to support an outcomes-based agreement in oncology? WY Cheung, C Cameron, A Mitha, A Wills Supportive Care in Cancer 31 (1), 5, 2023 | 2 | 2023 |
| A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry R Buckstein, L Chodirker, L Mozessohn, KWL Yee, M Geddes, N Zhu, ... Leukemia & Lymphoma 63 (13), 3165-3174, 2022 | 4 | 2022 |
| Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple … IA Samjoo, L Klotz, G Giovannoni, C Drudge, A Haltner, E Worthington, ... Multiple Sclerosis and Related Disorders 66, 104031, 2022 | 11 | 2022 |
| Letter to the editor regarding “Network meta-analysis of food and drug administration-approved treatment options for adults with aquaporin-4 immunoglobulin g-positive … BAC Cree, B Greenberg, C Cameron, BG Weinshenker Neurology and Therapy 11 (3), 1439-1443, 2022 | 6 | 2022 |
| HTA52 Comparing the Change from Base Case to Re-Analyzed ICER Values for CADTH Oncology Evaluations M Stino, S Shah, K Kipentzoglou, C Cameron Value in Health 25 (7), S513, 2022 | | 2022 |
| Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease … RS Douglas, R Dailey, PS Subramanian, G Barbesino, S Ugradar, ... JAMA ophthalmology 140 (4), 328-335, 2022 | 39 | 2022 |
| Ozanimod for the Treatment of Biologic-Experienced Patients with Moderate-to-Severe Ulcerative Colitis: Results from a Systematic Literature Review and Network Meta-Analyses K Eaton, C Duperrouzel, P Bhandari, S Craigie, A Bonner, C Cameron, ... Value in Health 25 (1), S27-S28, 2022 | 1 | 2022 |
| Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses IA Samjoo, E Worthington, A Haltner, P Spin, C Drudge, C Cameron, ... Current Medical Research and Opinion 37 (11), 1933-1944, 2021 | 4 | 2021 |
| Thyroid eye disease and healthcare resource utilization CC Kossler AL, Batten R American Academy of Ophthalmology 2021; New Orleans, LA. Poster PO028, https …, 2021 | | 2021 |
| Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients … T Martin, SZ Usmani, JM Schecter, M Vogel, CC Jackson, W Deraedt, ... Current Medical Research and Opinion 37 (10), 1779-1788, 2021 | 34 | 2021 |
| Network Meta-analysis of Disease-modifying Therapies for Relapsing Multiple Sclerosis Based on Confirmed Disability Progression: Investigating the Influence of Cross-trial … D Stoneman, C Drudge, M Zhao, E Worthington, C Cameron, DA Haring, ... MULTIPLE SCLEROSIS JOURNAL 27 (2_ SUPPL), 736-737, 2021 | | 2021 |
| Relapse Reduction by Disease-modifying Therapies for Relapsing Multiple Sclerosis: A Network Meta-analysis D Stoneman, C Drudge, M Zhao, E Worthington, C Cameron, D Haring, ... MULTIPLE SCLEROSIS JOURNAL 27 (2_ SUPPL), 739-739, 2021 | | 2021 |
| Palbociclib versus abemaciclib in HR+/HER2-advanced breast cancer: an indirect comparison of patient-reported end points E Law, R Gavanji, S Walsh, A Haltner, R McTavish, C Cameron Journal of Comparative Effectiveness Research 11 (2), 109-120, 2021 | 7 | 2021 |
| Network meta-analysis of ulcerative colitis pharmacotherapies: carryover effects from induction and bias of the results D Naessens, C Cameron, DC Hoaglin Clinical Gastroenterology and Hepatology 19 (10), 2219-2221, 2021 | 2 | 2021 |
| Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and … S de Botton, JM Brandwein, AH Wei, A Pigneux, B Quesnel, X Thomas, ... Cancer Medicine 10 (18), 6336-6343, 2021 | 6 | 2021 |
Brian HuttonOttawa Hospital Research Institute, Senior Scientist在 ohri.ca 的电子邮件经过验证
